Table 1.
Baseline characteristics
| AZD8601 3 mg (n = 7) | Placebo (n = 4) | Overall (N = 11) | |
|---|---|---|---|
| Age, years | |||
| Median (range) | 68 (61–77) | 69.5 (53–79) | 69 (53–79) |
| Sex | |||
| Male, n (%) | 7 (100) | 2 (50) | 9 (81.8) |
| Female, n (%) | 0 (0) | 2 (50) | 2 (18.2) |
| White, n (%) | 7 (100) | 4 (100) | 11 (100) |
| Body mass index category | |||
| Normal (<25 kg/m2), n (%) | 4 (57.1) | 1 (25) | 5 (45.5) |
| Overweight (25–30 kg/m2), n (%) | 2 (28.6) | 3 (75) | 5 (45.5) |
| Obese (>30 kg/m2), n (%) | 1 (14.3) | 0 (0) | 1 (9.1) |
| Medical history (at least 50% of patients) | |||
| Coronary artery disease, n (%) | 7 (100) | 4 (100) | 11 (100) |
| Hypertension, n (%) | 7 (100) | 3 (75) | 10 (90.9) |
| Dyslipidemia, n (%) | 4 (57.1) | 4 (100) | 8 (72.7) |
| Left ventricular ejection fraction (Simpson method), % | |||
| Median (range) | 50.24 (25.03, 63.30) | 50.72 (40.85, 55.40) | |